A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. (Q52782650)
Jump to navigation
Jump to search
scientific article published on 8 March 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. |
scientific article published on 8 March 2017 |
Statements
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. (English)
1 reference
Ruben Niesvizky
1 reference
Koen Van Besien
1 reference
Tomer M Mark
1 reference
Danielle Guarneri
1 reference
Peter Forsberg
1 reference
Adriana Rossi
1 reference
Roger Pearse
1 reference
Arthur Perry
1 reference
Karen Pekle
1 reference
Linda Tegnestam
1 reference
June Greenberg
1 reference
Tsiporah Shore
1 reference
Usama Gergis
1 reference
Sebastian Mayer
1 reference
Scott Ely
1 reference
David Jayabalan
1 reference
Daniel Sherbenou
1 reference
Morton Coleman
1 reference
8 March 2017
1 reference
23
1 reference
930-937
1 reference
6
1 reference